Cargando…

Successful Treatment of Complicated Influenza A(H3N2) Virus Infection and Rhabdomyolysis with Compassionate Use of IV Zanamivir

In 2019, EMA licensed intravenous (IV) zanamivir for severe influenza virus infection in children over 6 months as well as adults. Prior to that, it was possible via a compassionate use program. We present successful compassionate use of IV zanamivir in a 14-year-old female with severe influenza A(H...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alchikh, Maren, Obermeier, Patrick E., Schweiger, Brunhilde, Rath, Barbara A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9865252/ https://www.ncbi.nlm.nih.gov/pubmed/36678583 http://dx.doi.org/10.3390/ph16010085

Ejemplares similares

Incidence, Disease Severity, and Follow-Up of Influenza A/A, A/B, and B/B Virus Dual Infections in Children: A Hospital-Based Digital Surveillance Program
por: Obermeier, Patrick E., et al.
Publicado: (2022)

1062 Compassionate Use of Intravenous (IV) Zanamivir During the 2013-2014 Influenza Season: Case Series of Three Patients
por: Shah, Punit, et al.
Publicado: (2014)

Linking digital surveillance and in-depth virology to study clinical patterns of viral respiratory infections in vulnerable patient populations
por: Obermeier, Patrick E., et al.
Publicado: (2022)

Partnering for enhanced digital surveillance of influenza‐like disease and the effect of antivirals and vaccines (PEDSIDEA)
por: Rath, Barbara, et al.
Publicado: (2019)

Zanamivir aqueous solution in severe influenza: A global Compassionate Use Program, 2009–2019
por: Wang‐Jairaj, Jie, et al.
Publicado: (2021)

Intravenous zanamivir for influenza myocarditis and enteral malabsorption
por: Jahns, Fritz-Patrick, et al.
Publicado: (2018)

Lessons from resistance analysis in clinical trials of IV zanamivir
por: Yates, Phillip J, et al.
Publicado: (2023)

Development of oseltamivir and zanamivir resistance in influenza A(H1N1)pdm09 virus, Denmark, 2014
por: Trebbien, Ramona, et al.
Publicado: (2017)

Why are oseltamivir and zanamivir effective against the newly emerged influenza A virus (A/H1N1)?
por: Yu, Kunqian, et al.
Publicado: (2009)

Oseltamivir/zanamivir: Lack of efficacy leading to fatal influenza A (H1N1) infection: case report
Publicado: (2013)

Diagnostic Approach for the Differentiation of the Pandemic Influenza A(H1N1)v Virus from Recent Human Influenza Viruses by Real-Time PCR
por: Schulze, Martin, et al.
Publicado: (2010)

Comparison of efficacy and safety of oseltamivir and zanamivir in pandemic influenza treatment
por: Tuna, Nazan, et al.
Publicado: (2012)

IF-03 Clinical Effectiveness of Oseltamivir or Zanamivir for Influenza A/H1N1 Virus with or without H274Y Mutation
por: Kawai, Naoki, et al.
Publicado: (2009)

Oseltamivir-Resistant Pandemic (H1N1) 2009 Treated with Nebulized Zanamivir
por: Da Dalt, Liviana, et al.
Publicado: (2010)

Zanamivir for the prevention of influenza in adults and children age 5 years and older
por: Eiland, Lea S, et al.
Publicado: (2007)

Zanamivir should be inhaled, not nebulised
por: Eagel, Barry A
Publicado: (2010)

Prone position ventilation, recruitment maneuver and intravenous zanamivir in severe refractory hypoxemia caused by influenza A (H1N1)
por: Biatto, Jair F P, et al.
Publicado: (2010)

Comparison of the clinical effectiveness of zanamivir and laninamivir octanoate for children with influenza A(H3N2) and B in the 2011–2012 season
por: Koseki, Naoko, et al.
Publicado: (2014)

Treatment of Immunocompromised, Critically Ill Patients with Influenza A H1N1 Infection with a Combination of Oseltamivir, Amantadine, and Zanamivir
por: Meijer, Wouter J., et al.
Publicado: (2015)

Alloferon and Zanamivir Show Effective Antiviral Activity against Influenza A Virus (H1N1) Infection In Vitro and In Vivo
por: Lee, Dahae, et al.
Publicado: (2022)

Severe myocarditis due to influenza A(H1N1)pdm09 viral infection in a young woman successfully treated with intravenous zanamivir: A case report
por: Mazzitelli, Maria, et al.
Publicado: (2019)

Evaluation of the Antiviral Response to Zanamivir Administered Intravenously for Treatment of Critically Ill Patients With Pandemic Influenza A (H1N1) Infection
por: Fraaij, P. L. A., et al.
Publicado: (2011)

Zanamivir versus trivalent split virus influenza vaccine: a pilot randomized trial
por: Coleman, Brenda L, et al.
Publicado: (2015)

Molecular modeling and lead design of substituted zanamivir derivatives as potent anti-influenza drugs
por: Dholakia, Dhwani, et al.
Publicado: (2016)

Laboratory Exposure to Influenza A H2N2, Germany, 2004–2005
por: Schrauder, Annette, et al.
Publicado: (2006)

A two-year survey of the oseltamivir-resistant influenza A(H1N1) virus in Yamagata, Japan and the clinical effectiveness of oseltamivir and zanamivir
por: Matsuzaki, Yoko, et al.
Publicado: (2010)

Severe Influenza A(H1N1) Virus Infection Complicated by Myositis, Refractory Rhabdomyolysis, and Compartment Syndrome
por: Odio, Camila D., et al.
Publicado: (2019)

Clinical outcomes of patients treated with intravenous zanamivir for severe influenza A(H1N1)pdm09 infection: a case report series
por: Torti, Carlo, et al.
Publicado: (2019)

In Silico Studies Reveal Peramivir and Zanamivir as an Optimal Drug Treatment Even If H7N9 Avian Type Influenza Virus Acquires Further Resistance
por: Sarukhanyan, Edita, et al.
Publicado: (2022)

Generation and characterisation of monoclonal antibodies against influenza virus A, subtype H5N1
por: Linke, Sonja, et al.
Publicado: (2011)

Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments
por: Heneghan, Carl J, et al.
Publicado: (2014)

The Intranasal Application of Zanamivir and Carrageenan Is Synergistically Active against Influenza A Virus in the Murine Model
por: Morokutti-Kurz, Martina, et al.
Publicado: (2015)

A Review of Clinical Influenza A and B Infections With Reduced Susceptibility to Both Oseltamivir and Zanamivir
por: Abed, Yacine, et al.
Publicado: (2017)

Influenza C virus in pre-school children with respiratory infections: retrospective analysis of data from the national influenza surveillance system in Germany, 2012 to 2014
por: Fritsch, Annemarie, et al.
Publicado: (2019)

Quantitative Influenza Follow-Up Testing (QIFT)—A Novel Biomarker for the Monitoring of Disease Activity at the Point-of-Care
por: Chen, Xi, et al.
Publicado: (2014)

I223R Mutation in Influenza A(H1N1)pdm09 Neuraminidase Confers Reduced Susceptibility to Oseltamivir and Zanamivir and Enhanced Resistance with H275Y
por: LeGoff, Jérome, et al.
Publicado: (2012)

Myopericarditis and exertional rhabdomyolysis following an influenza A (H3N2) infection
por: Tseng, Guo-Shiang, et al.
Publicado: (2013)

Predominance of HA-222D/G Polymorphism in Influenza A(H1N1)pdm09 Viruses Associated with Fatal and Severe Outcomes Recently Circulating in Germany
por: Wedde, Marianne, et al.
Publicado: (2013)

Neuraminidase Inhibitor Zanamivir Ameliorates Collagen-Induced Arthritis
por: Sehnert, Bettina, et al.
Publicado: (2021)

Permeability Enhancers Dramatically Increase Zanamivir Absolute Bioavailability in Rats: Implications for an Orally Bioavailable Influenza Treatment
por: Holmes, Eric H., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_hqjfgabvd2k0cjvdp8dg407d4g